Filamon secures exclusive licence for groundbreaking anti-cancer drug
Filamon was awarded an exclusive license for a groundbreaking experimental anti-cancer drug developed by Australian university scientists. Australian clinical-stage drug development company, Filamon Limited, announced
New Australian biotechnology company to develop a drug blocking prostate cancer
A new Australian bio-technology company secures a licence to develop a drug to block the development of metastatic prostate cancer. Filamon Limited, an Australian drug
